EIF2AK4 and neoplasm: Pharmacological blocking and genetic knock-out of GCN2 drastically reduce tumor growth and boost T-cell activity in multiple murine tumor models, due to impaired PMN-MDSC differentiation and downregulation of PD-L1 and CD206207,208.